1. Show article details.

    Lineage Cell Therapeutics to Participate in Maxim Group and M-Vest COVID-19 Virtual Conference Series on May 27, 2020

    Business Wire – 8:00 AM ET 05/19/2020

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be participating in the Maxim Group and M-Vest COVID-19 Virtual Conference Series: The Role of Cell Therapy and Clarity on Testing on May 27, 2020 at 10:00 am Eastern Time.

  2. Show article details.

    Lineage Cell Therapeutics to Present at 2020 Solebury Trout Virtual Investor Conference on May 26, 2020

    Business Wire – 8:00 AM ET 05/18/2020

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at the 2020 Solebury Trout Virtual Investor Conference on May 26, 2020 at 2:30 pm Eastern Time.

  3. Show article details.

    BRIEF-Lineage Cell Therapeutics Reports First Quarter Results

    Reuters – 5:32 PM ET 05/07/2020

    Lineage Cell Therapeutics Inc (LCTX): * LINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE. * Q1 REVENUE $500,000 VERSUS $900,000. * Q1 REVENUE ESTIMATE $711,000 -- REFINITIV IBES DATA. * ANTICIPATE OUR NET OPERATIONAL SPEND FOR 2020 WILL INCREASE MODESTLY. * QTRLY LOSS PER SHARE $0.06 Source text for Eikon: Further company coverage:

  4. Show article details.

    Lineage Cell Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update

    Business Wire – 4:05 PM ET 05/07/2020

    CARLSBAD, Calif. “Lineage has adapted quickly to an unprecedented business environment. 2020 Plans and Objectives: - Present new OpRegen data from the ongoing Phase 1/2a clinical trial as available throughout the year.

  5. Show article details.

    BRIEF-Lineage Cell Therapeutics Announces Early Exercise Of Option With Cancer Research UK For Immuno-Oncology Cell Therapy Program

    Reuters – 8:51 AM ET 05/07/2020

    Lineage Cell Therapeutics Inc (LCTX): * LINEAGE CELL THERAPEUTICS ANNOUNCES EARLY EXERCISE OF OPTION WITH CANCER RESEARCH UK FOR IMMUNO-ONCOLOGY CELL THERAPY PROGRAM. * Lineage Cell Therapeutics Inc (LCTX) - LINEAGE WILL ASSUME RESPONSIBILITY FOR FURTHER DEVELOPMENT OF VAC2 PRODUCT CANDIDATE.

  6. Show article details.

    Lineage Cell Therapeutics Announces Early Exercise of Option with Cancer Research UK for Immuno-Oncology Cell Therapy Program

    Business Wire – 8:00 AM ET 05/07/2020

    CARLSBAD, Calif. “Clinical data recently collected by Cancer Research UK in the ongoing trial of VAC2 has shown peripheral immunogenicity in patients with non-small cell lung cancer, providing validation of the underlying mechanism of using allogeneic dendritic cells to present antigens to the body’s immune system.

  7. Show article details.

    Lineage Cell Therapeutics Reports New Data With OpRegen for the Treatment of Dry AMD With Geographic Atrophy

    Business Wire – 9:05 AM ET 05/06/2020

    CARLSBAD, Calif.

  8. Show article details.

    Lineage Cell Therapeutics to Apply Allogeneic Dendritic Cell Therapy Program to COVID-19 Vaccine Development

    Business Wire – 8:00 AM ET 05/05/2020

    Grant Application Submitted to California Institute for Regenerative Medicine for Additional Funding Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it has applied for grant funding from the California Institute for Regenerative Medicine to support the use of VAC, Lineage’s allogeneic dendritic...

  9. Show article details.

    BRIEF-Lineage Cell Therapeutics Inc Files For Mixed Shelf Of Upto $75 Million - SEC Filing

    Reuters – 5:24 PM ET 05/01/2020

    Lineage Cell Therapeutics Inc (LCTX): * LINEAGE CELL THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $75 MILLION - SEC FILING Source text for Eikon: https://bit.ly/3bWWCj8 Further company coverage:

  10. Show article details.

    Lineage Cell Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update on May 7, 2020

    Business Wire – 8:00 AM ET 04/29/2020

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will report its first quarter 2020 financial and operating results on Thursday, May 7, 2020, following the close of the U.S. financial markets.

  11. Show article details.

    BRIEF-Lineage Cell Therapeutics Conducts Sale Of Shares In Oncocyte Corporation

    Reuters – 8:30 AM ET 04/24/2020

    Lineage Cell Therapeutics Inc (LCTX): * LINEAGE CELL THERAPEUTICS CONDUCTS SALE OF SHARES IN ONCOCYTE CORPORATION. * Lineage Cell Therapeutics Inc (LCTX) - PRICING OF SALE OF 1.7 MILLION ONCOCYTE SHARES AT A PRICE TO BUYERS OF $2.27 PER SHARE. * Lineage Cell Therapeutics Inc (LCTX) - NET PROCEEDS FROM SALE OF ONCOCYTE SHARES WERE ABOUT $3.7 MILLION Source text for Eikon: Further company coverage:

  12. Show article details.

    Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation

    Business Wire – 8:00 AM ET 04/24/2020

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced the pricing of the sale of 1,672,689 shares of common stock of OncoCyte Corporation at a price to buyers of $2.27 per share, representing the closing price of OncoCyte common stock on April 23, 2020.

  13. Show article details.

    BRIEF-Lineage Cell Therapeutics Reports Quarterly Loss Per Share Of $0.03

    Reuters – 5:58 PM ET 03/12/2020

    Lineage Cell Therapeutics Inc (LCTX): * LINEAGE CELL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE. * Q4 REVENUE $1.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $1 MILLION. * ANTICIPATES NET OPERATIONAL SPEND FOR 2020 WILL BE ABOUT $16 MILLION. * QTRLY LOSS PER SHARE $0.03 Source text for Eikon: Further company coverage:

  14. Show article details.

    Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    Business Wire – 4:05 PM ET 03/12/2020

    CARLSBAD, Calif. “2019 was a transformative year for Lineage. Significant events and data updates from 2019 and early 2020 include: Potential key events for 2020: Balance Sheet Highlights Cash, cash equivalents, and marketable securities totaled $30.7 million as of December 31, 2019. During 2019, we were able to fund our operations primarily by selling a portion of our marketable securities.

  15. Show article details.

    Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update on March 12, 2020

    Business Wire – 8:00 AM ET 03/05/2020

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will report its fourth quarter and full year 2019 financial and operating results on Thursday, March 12, 2020, following the close of the U.S. financial markets.

Page:

Today's and Upcoming Events

  • Aug
    06

    LCTX to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    07

    LCTX announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.